Journal of Medical Toxicology

, Volume 5, Issue 2, pp 63–67 | Cite as

Dose-independent occurrence of seizure with tramadol

  • Haleh Talaie
  • Reyhaneh Panahandeh
  • Mohammad Reza Fayaznouri
  • Zahra Asadi
  • Mohammad Abdollahi
Toxicology Investigations



Tramadol, as a centrally-acting, opioid-like analgesic with serotonin reuptake inhibition property, is one of the most prescribed analgesics in the world. We assessed the incidence of seizure, as it is one of the most important adverse effects.


In a cross-sectional study, 215 cases of tramadol users or abusers who were admitted to Loghman-Hakim Hospital Poisoning Center (LHHPC) in Tehran during a 5-month period, from April 2007 to September 2007, were assessed to evaluate the occurrence of seizure. Patients with positive history of co-ingestion of other drugs, addiction, convulsive disorders, renal diseases, or head trauma with abnormal electroencephalography (EEG) or computerized tomography (CT) scan of the brain were excluded, thus 132 patients were included in the study. For patients who had seizure, CT scan of the brain and EEG were performed, and frequency and type of seizure were identified. Mean tramadol dose was compared between patients with and without seizure.


Among the patients, 97 (73.5%) were male. Seizure occurred in 61 patients (46.2%) within 24 hours after tramadol ingestion. The majority of patients who had seizure were male (male, 83.6% vs. female, 16.4%). Mean tramadol dose was lower among females than males (males, 2413 mg vs. females, 1706 mg), but the difference was not statistically significant. Of 35 patients with documented seizure type, all showed generalized tonic-clonic seizure and 12 patients had abnormal EEG (35.3%). No statistically significant difference was observed in mean tramadol intake between patients with or without seizure. Analysis of patients with seizure, according to tramadol intake, indicated that most patients used tramadol in the dose range of 500–1000 mg followed in occurrence by 1500–2000 mg, then 100–500 mg, 2500–3000 mg, and 3500–4000 mg.


Mean tramadol intake does not differ between patients with and without seizure, and the most common dose range in those with seizure is 500–1000 mg. We thus conclude that the incidence of seizure with tramadol is not dose dependent.


tramadol seizure toxicity 


  1. 1.
    Frink MC, Hennies HH, Englberger W, et al. Influence of tramadol on neurotransmitter systems of the rat brain.Arzneimittelforschung 1996;46:1029–1036.PubMedGoogle Scholar
  2. 2.
    Lai J, Ma SW, Porreca F, et al. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells.Eur J Pharmacol 1996;316:369–372.PubMedCrossRefGoogle Scholar
  3. 3.
    Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M. Monitoring of National Drug Policy (NDP) and its standardized indicators: conformity to decisions of the national drug selecting committee in Iran.BMC Int Health Hum Rights 2005;5:5.PubMedCrossRefGoogle Scholar
  4. 4.
    De Decker K, Cordonnier J, Jacobs W, et al. Fatal intoxication due to tramadol alone; case report and review of the literature.Forensic Sci Int 2008;175(1):79–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine.Drug Alcohol Depend 1991;27:7–17.PubMedCrossRefGoogle Scholar
  6. 6.
    Cami J, Lamas X, Farre M. Acute effects of tramadol in methadone-maintained volunteers.Drugs 1994;47:39–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Knisely JS, Campbell ED, Dawson KS, et al. Tramadol postmarketing surveillance in health care professionals.Drug Alcohol Depend 2002;68:15–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Klotz U. Tramadol—the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain.Arzneimittelforschung 2003;53:681–687.PubMedGoogle Scholar
  9. 9.
    Richter W, Barth H, Flohé L, et al. Clinical investigation on the development of dependence during oral therapy with tramadol.Arzneimittelforschung 1985;35:1742–1744.PubMedGoogle Scholar
  10. 10.
    Shipton EA. Tramadol—present and future.Anaesth Intensive Care 2000;28:363–374.PubMedGoogle Scholar
  11. 11.
    Grond S, Sablotzki A. Clinical pharmacology of tramadol.Clin Pharmacokinet 2004;43:879–923.PubMedCrossRefGoogle Scholar
  12. 12.
    McDiarmid T, Mackler L, Schneider DM. Clinical inquiries. What is the addiction risk associated with tramadol?J Fam Pract 2005;54:72–73.PubMedGoogle Scholar
  13. 13.
    Clarot F, Goulle JP, Vaz E, et al. Fatal overdoses of tramadol: is benzodiazepine a risk factor of lethality?Forensic Sci Int 2003;134:57–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Marquardt KA, Alsop JA, Albertson TE. Tramadol exposures reported to statewide poison control system.Ann Pharmacother 2005;39:1039–1044.PubMedCrossRefGoogle Scholar
  15. 15.
    Jovanović-Cupić V, Martinovic Z, Nesic N. Seizures associated with intoxication and abuse of tramadol.Clin Toxicol (Phila) 2006;44:143–146.Google Scholar
  16. 16.
    Abdollahi M, Jalali N, Sabzevari O, et al. A retrospective study of poisoning in Tehran.J Toxicol/Clin Toxicol 1997;35(4): 387–393.Google Scholar
  17. 17.
    Shadnia S, Esmaily H, Sasanian G, et al. Pattern of acute poisoning in Tehran-Iran in 2003.Hum Exp Toxicol 2007;26: 753–756.PubMedCrossRefGoogle Scholar
  18. 18.
    Moghadamnia AA, Abdollahi M. An epidemiological study of acute poisonings in northern Islamic Republic of Iran.East Mediterr Health J 2002;8(1):88–94.PubMedGoogle Scholar
  19. 19.
    Kahn LH, Alderfer RJ, Graham DJ. Seizures reported with tramadol.JAMA 1997;278:1661.PubMedCrossRefGoogle Scholar
  20. 20.
    Spiller HA, Gorman SE, Villalobos D, et al. Prospective multicenter evaluation of tramadol exposure.J Toxicol/Clin Toxicol 1997;35:361–364.Google Scholar
  21. 21.
    Ultram, Ortho-McNeil Pharmaceuticals. Physician’s Desk Reference. 53rd ed. Montvale, NJ: Medical Economics, 1999, pp. 2254–2257.Google Scholar
  22. 22.
    Gholami K, Shalviri G, Zarbakhsh A, et al. New guideline for tramadol usage following adverse drug reactions reported to the Iranian Pharmacovigilance Center.Pharmacoepidemiol Drug Saf 2007;16:229–237.PubMedCrossRefGoogle Scholar
  23. 23.
    Gardner JS, Blough D, Drinkard CR, Shatin D, et al. Tramadol and seizures: a surveillance study in a managed care population.Pharmacotherapy 2000;20:1423–1431.PubMedCrossRefGoogle Scholar
  24. 24.
    Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H. Incidence of first-time idiopathic seizures in users of tramadol.Pharmacotherapy 2000;20:629–634.PubMedCrossRefGoogle Scholar
  25. 25.
    Jick H, Derby LE, Vasilakis C, et al. The risk of seizures associated with tramadol.Pharmacotherapy 1998;18: 607–611.PubMedGoogle Scholar
  26. 26.
    Labate A, Newton MR, Vernon GM, et al. Tramadol and new-onset seizures.Med J Aust 2005;182:42–43.PubMedGoogle Scholar
  27. 27.
    Manocha A, Sharma KK, Mediratta PK. Tramadol, a centrally acting opioid: anticonvulsant effect against maximal electroshock seizure in mice.Indian J Physiol Pharmacol 1998;42:407–411.PubMedGoogle Scholar
  28. 28.
    Shadnia S, Soltaninejad K, Heydaril K, et al. Tramadol intoxication: a review of 114 cases.Hum Exp Toxicol 2008;27: 201–205.PubMedCrossRefGoogle Scholar

Copyright information

© American College of Medical Toxicology 2009

Authors and Affiliations

  • Haleh Talaie
    • 1
  • Reyhaneh Panahandeh
    • 1
  • Mohammad Reza Fayaznouri
    • 2
  • Zahra Asadi
    • 1
  • Mohammad Abdollahi
    • 3
  1. 1.Toxicological Research Center, and Poison Center, Loghman-Hakim Hospital, School of MedicineShaheed Beheshti University of Medical SciencesTehranIran
  2. 2.Iranian National Center for Addiction StudyTehran University of Medical SciencesTehranIran
  3. 3.Faculty of Pharmacy, and Pharmaceutical Sciences Research CenterTehran University of Medical SciencesTehranIran

Personalised recommendations